Medically reviewed by Geetika Gupta, MDIf you have eczema, you may be concerned that COVID-19 vaccines will trigger symptoms.

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Novartis has axed development of its mid-stage eczema drug ZPL389 ... towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis.

and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent ...

Sanofi’s Dupixent (dupilumab) has been cleared for NHS funding in Wales and Scotland in adolescents with severe eczema, also known as atopic dermatitis. The decisions from the All Wales ...

Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 23.8% to 3.48 billion euros. Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma ...

The study’s primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin ...

and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent (dupilumab).